Quick Answer
Candel Therapeutics, Inc. reported Stockholders Equity of $51.92 million for fiscal year 2025.
Candel Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $51.92M | -21.7% |
| 2024 | $66.33M | +420.4% |
| 2023 | $12.74M | -73.3% |
| 2022 | $47.71M | -25.6% |
| 2021 | $64.14M | +372.2% |
| 2020 | -$23.56M | -193.1% |
| 2019 | -$8.04M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $80.12M | +625.2% | -11.2% |
| June 30, 2025 | $90.21M | +1004.6% | +20.8% |
| March 31, 2025 | $74.67M | +1149.0% | +12.6% |
| December 31, 2024 | $66.33M | +420.4% | +534.7% |
| September 30, 2024 | -$15.26M | -166.3% | -53.0% |
| June 30, 2024 | -$9.97M | -132.4% | -266.8% |
| March 31, 2024 | $5.98M | -84.9% | -53.1% |
| December 31, 2023 | $12.74M | -73.3% | -44.6% |
- Candel Therapeutics, Inc. showed a decrease of -21.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Candel Therapeutics, Inc.’s stockholders equity has grown by 746.0% (from -$8.04 million to $51.92 million).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: